A study looking at the impact of pneumococcal vaccine introduction and scaling up pneumonia treatment in Ethiopia found that 30-40% of all deaths averted by these interventions would be expected to occur in the poorest wealth quintile. Scaling up PCV13 to levels achieved with DTP3 in Ethiopia would be expected to avert nearly 3000 child deaths and 60,000 episodes of pneumococcal pneumonia annually, not including any potential herd benefit. A publicly financed program to scale up pneumococcal vaccines would cost about US$40 per year of healthy life gained.
Full Citation:
Johannsen, K.A, Memirie, S.T., Pecenka, C. et al. 2015. Health gains and financial protection from pneumococcal vaccination and pneumonia treatment in Ethiopia: Results from an extended cost-effectiveness analysis. PLOS ONE. 10(12).
Title of Article: Health gains and financial protection from pneumococcal vaccination and pneumonia treatment in Ethiopia: Results from an extended cost-effectiveness analysis
Author(s): Johannsen, K.A, Memirie, S.T., Pecenka, C. et al
Publication Year: 2015
Publication Name: PLOS ONE
Publication Volume: 10(12)
Publication Source URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674114/
DOI (Digital Object Identifier): 10.1371/journal.pone.0142691
Topics: Equity
Disease Vaccines: Pneumococcal disease/PCV/PPSV | Pneumonia
Countries: Ethiopia
WHO Regions: Africa